Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin

Clinical Pharmacology and Therapeutics

Volumn 62, Issue 4, 1997, Pages 384-391

  Böttiger, Ylva ^a   Tybring, Gunnel ^a   Götharson, Eva ^a   Bertilsson, Leif ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 ISOENZYME; KETOCONAZOLE; MEPHENYTOIN; OMEPRAZOLE; OMEPRAZOLE SULFONE; PROTON PUMP INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG METABOLISM; FEMALE; GENETIC POLYMORPHISM; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VOLUNTEER;

ADULT; AGED; ANTI-ULCER AGENTS; ANTICONVULSANTS; ANTIFUNGAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; HUMANS; KETOCONAZOLE; MALE; MEPHENYTOIN; MIDDLE AGED; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; OXIDATION-REDUCTION; TIME FACTORS;

EID: 0030662173     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(97)90116-8     Document Type: Article

References (19)

1. Walan A. Clinical experience with omeprazole: assessment of efficacy and safety. Gastroenterol Hepatol 1989;4(suppl 2):27-33.
2. Regårdh CG. Pharmacokinetics and metabolism of omeprazole in man. Scand J Gastroenterol 1986; 21(suppl 118):99-104.
3. Andersson T, Regårdh CG, Dahl-Puustinen ML, Bertilsson L. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 1990; 12:415-6.
4. Andersson T, Regårdh CG, Lou YC, Zhang Y, Dahl ML, Bertilsson L. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992;2: 25-31.
5. Chang M, Dahl ML, Tybring G, Götharson E, Bertilsson L. Use of omeprazole as probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995;5: 358-63.
6. Andersson T, Miners JO, Veronese M, Tassaneeyakul W, Tassaneeyakul W, Meyer UA, et al. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 1993; 36:521-30.
7. Alvan G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990;39:533-7.
8. Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors: focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996;31:9-28.
9. Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF, Benet LZ. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 1995;58;15-9.
10. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;56:601-7.
11. Krishnaiah YS, Satyanarayana S, Visweswaram D. Interaction between tolbutamide and ketoconazole in healthy subjects. Br J Clin Pharmacol 1994;37: 205-7.
12. Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and S-mephenytoin. Clin Pharmacol Ther 1992;51:388-97.
13. Tybring G, Böttiger Y, Widén J, Bertilsson L. Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish healthy subjects. Clin Pharmacol Ther 1997;62:129-37.
14. Riley CM, James MO. Determination of ketoconazole in the plasma, liver, lung and adrenal of the rat by high-performance liquid chromatography. J Chromatogr 1986;377:287-94.
15. Rost KL, Roots I. Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19. Hepatology 1996;23:1491-7.
16. Dahl ML, Voortman G, Alm C, Elwin CE, Delbressine L, Vos R, et al. In vitro and in vivo studies on the disposition of mirtazapine in humans. Clin Drug Invest 1997;13:37-46.
17. Sood A, Sharma M, Jain NP, Chawla LS. Esophageal candidiasis following omeprazole therapy: a report of two cases. Indian J Gastroenterol 1995;14:71-2.
18. Mosimann F. Esophageal candidiasis, omeprazole therapy, and organ transplantation - word of caution. Transplantation 1993;56:492-3.
19. Teare JP, Spedding C, Whitehead MW, Greenfield SM, Challacombe SJ, Thompson RP. Omeprazole and dry mouth. Scand J Gastroenterol 1995;30: 216-8.